Date: 2015-07-02
Type of information: Nomination
Compound:
Company: Genticel (France)
Therapeutic area: Cancer - Oncology - Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On July 2, 2015, Genticel, a clinical-stage biotechnology company and developer of innovative immunotherapies to prevent cancers caused by the human papillomavirus (HPV), announces that, upon the proposal of Benedikt Timmerman, Genticel’s Supervisory Board has appointed Martin Koch, CFO, as the Company’s CEO for the next 3 months while Mr. Timmerman recovers from several accidental lower limb fractures. Mr. Timmerman remains on Genticel’s Executive Management Board and will provide strategic counsel to the team during this period before resuming his position this fall.
Martin Koch, M.Sc. Eng., MBA, 53, joined Genticel as CFO in September 2007 with over 20 years of financial and operational experience in the life sciences industry. He is a member of the Executive Management Board. Working closely with Mr. Timmerman for the past 8 years, Mr. Koch oversees all financial and administrative operations of the Company.
Financial terms:
Latest news:
